Efforts to engineer CAR Ts, NKs, TCRs, and TILs with greater precision, safety profiles, and efficacy are leading to the second generation of .. Read more improved adoptive cell therapies. With multiple engineered receptors already making preclinical impact, many biotech and pharma companies are preparing for the next wave of clinical trials. The end goal is still the same: improved patient outcomes. However, there remain technical considerations and translational challenges relating to cell therapy development, manufacturing practicability, clinical trial approaches, cell quality and persistence, and patient management. Cambridge Healthtech Institute’s Seventh Annual Adoptive Cell Therapy conference focuses on the next steps needed to deliver CAR Ts, TCRs, and TILs into the clinic.
- [ Users who have shown interest for this Event ]
- Share your Experience
More Events From The Organizer
- Oligonucleotide Discovery and ..20 - 21 Oct 2020Boston